GLP-1 Drugs and Kidney Disease - The Trial That Changed Everything

Impossible d'ajouter des articles

Désolé, nous ne sommes pas en mesure d'ajouter l'article car votre panier est déjà plein.

Veuillez réessayer plus tard

Échec de l’élimination de la liste d'envies.

Veuillez réessayer plus tard

Impossible de suivre le podcast

Impossible de ne plus suivre le podcast

GLP-1 Drugs and Kidney Disease - The Trial That Changed Everything

Écouter gratuitement

Voir les détails

À propos de ce contenu audio

Julia Cartwright explores how the FLOW trial revealed GLP-1 drugs like semaglutide offer groundbreaking kidney protection for diabetic patients, reducing kidney failure risk by 24%—results so powerful the study stopped early, establishing a fourth pillar in chronic kidney disease treatment alongside existing therapies.

Loved this episode? Discover more original shows from the Quiet Please Network at QuietPlease.ai, explore our curated favorites here amzn.to/42YoQGI, and catch just a slice of our AI hosts in action on Instagram at instagram.com/claredelish and YouTube at youtube.com/@DIYHOMEGARDENTV

This content was created in partnership and with the help of Artificial Intelligence AI

Aucun commentaire pour le moment